Tiziana Life Sciences Ltd. has been awarded a grant by the U.S. Department of Defense to advance its intranasal anti-CD3 therapy for traumatic spinal cord injury. This funding will support a three-year study focusing on the acute phase of spinal cord injury, targeting patients immediately after trauma. Additionally, a two-year Stepping Strong Breakthrough Award will extend research into the chronic phase, addressing long-term neurological deficits. The initiative marks a significant step in exploring the therapeutic potential of Tiziana's intranasal anti-CD3 platform beyond its current applications in autoimmune and neuroinflammatory diseases. Collaborating with researchers at Brigham and Women's Hospital, Tiziana aims to develop a non-invasive treatment that could improve quality of life for nearly 300,000 Americans living with permanent spinal cord disabilities.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-087418), on September 15, 2025, and is solely responsible for the information contained therein.
Comments